文献速递胸部肿瘤放疗放疗物理与技术

预测早期非小细胞肺癌立体定向消融放疗后5年进展与生存结局的列线图开发与验证

Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-10-03

该研究基于2004—2015年接受SABR的714例早期非小细胞肺癌患者(中位随访59个月),按8:2分为训练集与测试集,用LASSO筛选预测因子后建立Cox模型并构建5年OS、PFS、TTP列线图。训练集C-index分别为0.73、0.68、0.60,测试集为0.72、0.66、0.59;肿瘤>2.45 cm与PTV D95 BED10<113 Gy与局部和远处进展均显著相关。

要点

  • 列线图可预测SABR后5年OS、PFS、TTP,训练集C-index为0.73、0.68、0.60。
  • 肿瘤大小>2.45 cm和PTV D95 BED10<113 Gy与局部及远处进展显著相关。
  • 年龄、性别、CCI、DLCO、SII和肿瘤大小是OS与PFS的显著预测因子。

核心结论

  • 这些预后列线图可较准确预测ES-NSCLC患者SABR后5年的OS、PFS和TTP,有助于识别可能从额外全身治疗中获益的高危患者。

研究设计与样本

  • 回顾性队列纳入2004—2015年接受SABR的714例ES-NSCLC患者,中位随访59个月,按8:2分为训练集与测试集。
  • 采用LASSO筛选OS、PFS、TTP预测因子,再行Cox比例风险回归建模,以C-index和校准图验证列线图。

主要发现

  • 5年OS和PFS的显著预测因子包括年龄、性别、Charlson合并症指数、DLCO、系统免疫炎症指数和肿瘤大小(均P≤.01)。
  • ECOG体能状态也预测OS(P=.01);肿瘤大小(P<.01)和PTV D95 BED10(P<.01)预测TTP。
  • OS、PFS、TTP列线图C-index在训练集分别为0.73、0.68、0.60,在测试集分别为0.72、0.66、0.59。
  • 肿瘤大小>2.45 cm和PTV D95 BED10<113 Gy与局部和远处进展均显著相关。

关键数值与推荐

  • 肿瘤大小>2.45 cm和PTV D95 BED10<113 Gy与局部及远处进展显著相关。
  • 多变量回归中P<.05的预测因子被纳入列线图。
  • OS、PFS、TTP列线图C-index在训练集为0.73、0.68、0.60,测试集为0.72、0.66、0.59。

临床怎么用

  • 可用于SABR后5年OS、PFS、TTP风险分层,辅助识别高危患者并考虑追加全身治疗。
  • 肿瘤大小>2.45 cm或PTV D95 BED10<113 Gy提示局部和远处进展风险较高。

局限性

  • 原文未报告列线图的外部验证队列及前瞻性验证结果。
  • 原文未报告列线图在临床决策中的干预性研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to develop predictive nomograms for overall survival (OS), progression-free survival (PFS), and time-to-progression (TTP) at 5 years in patients with early-stage non-small cell lung cancer (ES-NSCLC) treated with stereotactic ablative radiation therapy (SABR). METHODS AND MATERIALS: The study cohort included 714 ES-NSCLC patients treated with SABR from 2004-2015 with median follow-up of 59 months, divided into training and testing sets (8:2), with the former used for nomogram development. The least absolute shrinkage and selection operator were initially employed to screen for predictors of OS, PFS, and TTP, and identified predictors were subsequently applied toward Cox proportional hazards regression modeling. Significant predictors (P < .05) on multivariable regression were then used to develop nomograms, which were validated via evaluation of concordance indexes (C-index) and calibration plots. Finally, Kaplan-Meier method and Gray's test were employed to compare and confirm differences in outcomes among various groups and explore prognostic factors associated with local versus distant disease progression. RESULTS: Significant predictors of both OS and PFS at 5 years included age, sex, Charlson comorbidity index, diffusing capacity of carbon monoxide, systemic immune-inflammation index, and tumor size (P ≤ .01 for all). Eastern Cooperative Oncology Group performance status predicted for OS as well (P = .01), and both tumor size (P < .01) and minimum biological equivalent dose to 95% of planning target volume (PTV D95 BED10; P < .01) were predictive of TTP. The C-indexes for the OS, PFS, and TTP nomograms were 0.73, 0.68, and 0.60 in the training data set and 0.72, 0.66, and 0.59 in the testing data set, respectively. Tumor size > 2.45 cm and PTV D95 BED10 < 113 Gy were significantly associated with both local and distant progression. CONCLUSIONS: These prognostic nomograms can accurately predict for OS, PFS, and TTP at 5 years after SABR for ES-NSCLC and may thus help identify high-risk patients who could benefit from additional systemic therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kang J, Ning MS, Feng H, et al. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. Int J Radiat Oncol Biol Phys. 2019. PMID: 31586665. doi:10.1016/j.ijrobp.2019.09.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。